Schizoaffective Disorder & Pregnancy
Deciding what to do about medication during pregnancy is one of the hardest decisions many people with schizoaffective disorder face — and it's a decision that should be made with a psychiatrist and obstetrician together, not alone. This page lays out the general research landscape so you can have a more informed conversation with your care team, not to replace that conversation.
Last updated: August 2026
Written by Jay Fincher, based on lived experience with schizoaffective disorder, bipolar type. Sourced from the DSM-5, NIMH, and peer-reviewed literature (see references below). This page does not have a formal clinical reviewer yet — see a licensed provider for diagnosis or treatment decisions.
This page should be reviewed by a perinatal or reproductive psychiatry specialist given the medication-safety claims involved; it is one of the highest-stakes pages on this site from an accuracy standpoint.
Key Takeaways
- —Schizoaffective disorder, along with bipolar disorder, carries elevated risk of becoming unwell during pregnancy and the postpartum period compared to the general population.
- —Stopping antipsychotic medication during pregnancy is not automatically the safer choice — untreated relapse carries its own serious risks to both parent and baby.
- —Research has not found antipsychotic use in pregnancy to be significantly associated with increased risk of major congenital malformations, though other risks are still studied and monitored.
- —Continuing medication throughout pregnancy, rather than stopping and restarting near delivery, is associated with a lower risk of postpartum relapse.
- —If medication is paused, restarting an antipsychotic within 24 hours of birth is associated with lower postpartum psychosis risk.
- —This is a shared decision between you, your psychiatrist, and your obstetric team — not a decision to make from an article, including this one.
Why This Decision Is Hard
Pregnancy and the postpartum period can involve major changes in sleep, hormones, metabolism, stress, and daily support. Untreated or undertreated psychosis or mood episodes during pregnancy and after birth carry real risks of their own, including impaired functioning, difficulty attending prenatal care, unsafe decision-making, and hospitalization.
Research finds that pregnant women with schizophrenia-spectrum conditions frequently discontinue antipsychotics out of caution. That decision has been associated with higher relapse risk, particularly postpartum. The question is therefore not simply whether medication has risks, but how those risks compare with the risks of relapse for this specific person.
What the Research Says About Medication Safety
Current research has not found antipsychotic use in pregnancy to be significantly associated with an increased risk of major congenital malformations. This is reassuring but does not mean every medication, dose, or pregnancy has the same risk profile. Other outcomes continue to be studied and monitored, and medication decisions need to account for the individual's psychiatric history and physical health.
Continuity of treatment can matter more than avoiding medication altogether. Continuing an antipsychotic throughout pregnancy, rather than stopping and restarting close to delivery, has been associated with a lower risk of postpartum relapse. If medication is paused, research has associated restarting an antipsychotic within 24 hours of delivery with lower postpartum psychosis risk. These findings are general evidence, not instructions for changing a prescription.
Dose changes are common and expected during pregnancy because the body can absorb and process medication differently. After delivery, metabolism can return toward its previous baseline, so the dose may need reassessment postpartum. Only the prescribing clinician should make those changes.
Postpartum: A Higher-Risk Window
The weeks after birth are a known higher-risk period independent of pregnancy itself. Sleep loss, abrupt physical changes, pain, feeding demands, and the pressure of caring for a newborn can all make early warning signs harder to notice. Close postpartum psychiatric follow-up should be arranged before delivery rather than waiting for symptoms to become severe.
A written plan can identify warning signs, who should be called, how medication decisions will be handled, and who can help with the baby if the parent becomes unwell. The Caregiver Guide includes crisis-planning and communication steps that can be adapted to this situation.
Building Your Care Team
The recommended clinical approach is shared decision-making among the pregnant person, a psychiatrist, and the obstetric team. A useful care team may include:
- A perinatal psychiatrist experienced with psychotic-spectrum conditions and medication decisions during pregnancy and breastfeeding.
- An obstetrician who knows the psychiatric history, current medications, relapse pattern, and postpartum plan.
- A written postpartum warning-sign plan shared with a trusted support person, including emergency contact details and practical childcare backup.
Bring questions about medication safety, relapse history, sleep, feeding plans, dose monitoring, and what would trigger urgent help. Do not stop or restart an antipsychotic on your own; contact your treating team for individualized guidance.
On this site
- Medications — antipsychotics, mood stabilizers, side effects, and monitoring
- Caregiver Guide — communication, crisis planning, and support for loved ones
- Treatment — medication, therapy, and ongoing community support
External References & Further Reading
- Royal College of Psychiatrists — Antipsychotics in Pregnancy and Breastfeeding
- The British Journal of Psychiatry — Antipsychotic Continuation During Pregnancy and Risk of Postpartum Relapse
- NCBI PMC — Antipsychotic Drugs for Non-Affective Psychosis During Pregnancy and Postpartum
- NCBI PMC — Antipsychotic Use in Pregnancy